Clinical Trials
7 trialsNCT04825990 2026-06-01
POINT
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT06868433 2026-03-04
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
Phase 1 Recruiting
NCT06636734 2026-02-11
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
Phase 2 Recruiting
NCT04227509 2025-12-31
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Seoul National University Hospital
Phase 2 Completed
NCT07129772 2025-09-04
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
Phase 2 Not yet recruiting
NCT02538510 2024-11-26
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
Phase 1/2 Completed
NCT03544099 2023-04-11
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
National Health Research Institutes, Taiwan
Phase 2 Terminated